Skip to main content

Table 3 Occurrence of E. faecium biofilm formation by clinical source

From: In vitro activities of thiazolidione derivatives combined with daptomycin against clinical Enterococcus faecium strains

Clinical source (no. isolates tested)

No. (%) of isolates with biofilm phenotype

Strong

medium

Strong or medium

Weak

All positive

Blood (9)

1 (11.1)

1 (11.1)

2 (22.2)

3 (33.3)

5 (55.6)

Urine (55)

3 (5.5)

7 (12.7)

10 (18.2)

19 (34.5)

29 (52.7)

Pus or secretions (10)

2 (20.0)

0 (0.0)

2 (20.0)

3 (30.0)

5 (50.0)

Bile (6)

1 (16.7)

1 (16.7)

2 (33.3)

2 (33.3)

4 (66.7)

Othera (22)

1 (4.5)

3 (13.6)

4 (18.2)

7 (31.8)

11 (50.0)

Total (102)

8 (7.8)

12 (11.8)

20 (19.6)

34 (33.3)

54 (52.9)

  1. a Other sources contained sputum, ear swab, feces, catheter, pleural effusion, ascites fluid, drainage fluid and bronchoalveolar lavage fluid